Nicotine sensitizes the mouse brain to the addictive effects of cocaine, according to recent NIDA-supported research. The results accord with the hypothesis that a person’s initial use of an addictive substance physiologically sensitizes his or her brain to the rewarding and addictive effects of other substances. If the findings carry over to people, then preventing youths from smoking might reduce their vulnerability to cocaine abuse and addiction, and cocaine-dependent individuals might ease their path to recovery by quitting smoking.
March 2012 Dr. Thomas Kosten of Baylor College of Medicine and Dr. Peter Burkhard of the University of Connecticut are the recipients of NIDA’s 2011 Avant-Garde Awards for Innovative Medication Development Research. Dr. Kosten is developing a vaccine against methamphetamine abuse and Dr. Burkhard is developing a vaccine to counter nicotine addiction.
Towns that implemented a drug abuse prevention program called Communities That Care will see a return of $5.30 for each $1 they invested during the 5-year trial of the intervention, according to a cost-benefit analysis. The estimate is based on reductions in smoking and delinquency observed during the fourth year of the study among eighth-graders and the projected total costs of smoking, delinquency, and crime avoided over the lifetimes of study participants.
Men benefit more than women from nicotine replacement therapy for smoking cessation because nicotine affects a key neuroreceptor differently in the two sexes, a NIDA-sponsored study suggests. The findings highlight the need for alternative therapies for women smokers, and point to the female hormone progesterone as a potential therapeutic target.
April 2012 Dr. Volkow discusses NIDA’s efforts to develop effective antismoking treatments for populations with persistently high rates of smoking, such as people with psychiatric disorders, high school dropouts, and Native Americans.